Hintermeister, John G.Jones, Pamela D.Hoffmann, Walter E.Siegel, Arthur M.Dervisis, Nikolaos G.Kitchell, Barbara E.2016-11-152016-11-152008-11-010002-9645http://hdl.handle.net/10919/73454Objective—To evaluate the usefulness of carboxyterminal cross-linked telopeptide of type I collagen (ICTP) concentrations for screening dogs for the presence of osteosarcoma. Sample Population—32 client-owned dogs with osteosarcoma (27 dogs with osteosarcoma of the appendicular skeleton and 5 dogs with osteosarcoma of the axial skeleton) and 44 non–tumor-bearing control dogs. Procedures—Serum was obtained from blood samples collected from dogs with osteosarcoma and from clinically normal dogs. The serum ICTP concentration was determined by use of a commercially available radioimmunoassay for ICTP. Results—Mean ± SD serum ICTP concentration in the tumor-bearing dogs was 7.32 ± 2.88 ng/mL, and in clinically normal dogs, it was 6.77 ± 2.31 ng/mL; values did not differ significantly. Mean serum ICTP concentration in dogs with appendicular osteosarcoma, compared with that of clinically normal dogs, was not significantly different. Mean serum ICTP concentration in dogs with axial skeletal tumor location was 10.82 ± 2.31 ng/mL, compared with a value of 6.73 ± 2.28 ng/mL in dogs with appendicular osteosarcoma. Conclusions and Clinical Relevance—On the basis of the results of this study, serum ICTP concentrations are not a clinically useful screening tool for the detection of appendicular osteosarcoma in dogs. Despite the observation that serum ICTP concentration was higher in dogs with axial osteosarcoma than in clinically normal dogs, serum ICTP concentration determination is not a suitable screening test for osteosarcoma.1481 - 1486 (6) page(s)application/pdfenIn CopyrightVeterinary SciencesPRIMARY RIB TUMORSBONE METABOLISMAPPENDICULAR OSTEOSARCOMABIOCHEMICAL MARKERSLUNG-CARCINOMAMULTIPLE-MYELOMAURINARY MARKERSN-TELOPEPTIDEC-TELOPEPTIDETURNOVERArticle - Refereedhttps://doi.org/10.2460/ajvr.69.11.14816911